Publication Date
7-5-2024
Journal
Journal of Proteome Research
Abstract
Asparaginase-based therapy is a cornerstone in acute lymphoblastic leukemia (ALL) treatment, capitalizing on the methylation status of the asparagine synthetase (ASNS) gene, which renders ALL cells reliant on extracellular asparagine. Contrastingly, ASNS expression in acute myeloid leukemia (AML) has not been thoroughly investigated, despite studies suggesting that AML with chromosome 7/7q deletions might have reduced ASNS levels. Here, we leverage reverse phase protein arrays to measure ASNS expression in 810 AML patients and assess its impact on outcomes. We find that AML with inv(16) has the lowest overall ASNS expression. While AML with deletion 7/7q had ASNS levels slightly lower than those of AML without deletion 7/7q, this observation was not significant. Low ASNS expression correlated with improved overall survival (46 versus 54 weeks, respectively,
Keywords
Humans, Leukemia, Myeloid, Acute, Aspartate-Ammonia Ligase, Female, Proteomics, Male, Middle Aged, Adult, Aged, Chromosome Deletion, Protein Array Analysis, Asparaginase, Chromosomes, Human, Pair 7, Young Adult, Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
Supplementary Materials
PMID: 38829961